Evolving Strategies in Limited-Stage Small Cell Lung Cancer Management
Gerard A. Silvestri MD, MS, Master FCCP
Anurag Singh, MD
Adam H. Fox, MD, MSc
Mariam Alexander, MD, PhD
An Analysis of Subcutaneous Versus Intravenous Atezolizumab in NSCLC
AEGEAN Trial: The Role of Perioperative Durvalumab in NSCLC
Novel Immune Checkpoint Strategies in Non-Small Cell Lung Cancer Care
Jacob Sands, MD
Aakesh Desai, MD, MPH
NSCLC Care: Evaluating Durvalumab in the First-Line Setting
Liza Villaruz, MD
The Evolving Landscape of Targeted Therapies for Non-Small Cell Lung Cancer
Antibody-Drug Conjugates: An Emerging Approach in NSCLC Treatment
Challenging the Standard of Care in NSCLC: Findings from the TROPION-Lung01 Study
Managing Immunotherapy Toxicities in Lung Cancer Patients
Aliyah Pabani, MD
Recognizing the Role of Capmatinib for METex14 in NSCLC
Edward B. Garon, MD, MS
Checkpoint Inhibitor Combination Therapy for First-Line Advanced NSCLC
Shirish Gadgeel, MD
Exploring Advances in Treatment: A Step Forward in Small Cell Lung Cancer
Millie Das, MD
Evaluating Biomarkers at Work in NSCLC
Mark Awad, MD, PhD
Investigating Immunotherapy & Its Role in NSCLC
Concerning Kinases: Therapeutic Considerations for RET Rearranged NSCLC
D. Ross Camidge, MD, PhD
Assessing Quality of Care: Implementing a Lung Screening Program
Andrea B. McKee, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.